These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10219074)

  • 21. Effects of angiotensin II and of angiotensin converting enzyme inhibition in chronic renal failure.
    Ledingham JG
    Kidney Int Suppl; 1987 May; 20():S112-6. PubMed ID: 3037159
    [No Abstract]   [Full Text] [Related]  

  • 22. [Modes of intensive therapy for arterial hypertension in children with terminal chronic kidney failure].
    Sharipov AM
    Urologiia; 2002; (3):49-51. PubMed ID: 12180062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic renal disease: new therapies to delay kidney replacement.
    Michael B; Burke JF
    Geriatrics; 1994 Aug; 49(8):33-8. PubMed ID: 8039727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
    Rockx MA; Haddad H
    Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY; Li PK; Lui SF; Sanderson JE
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of calcium antagonist, angiotensin-converting enzyme inhibitors and beta-blocker on hemodynamic and sympathetic nerve responses to exercise in essential hypertension].
    Fujiwara S; Arita M; Ueno Y; Shiotani M; Nakatsu C; Nakamura Y; Hano T; Nishio I; Masuyama Y
    J Cardiol; 1991; 21(1):115-24. PubMed ID: 1687786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice.
    Jackson KL; Marques FZ; Watson AM; Palma-Rigo K; Nguyen-Huu TP; Morris BJ; Charchar FJ; Davern PJ; Head GA
    Hypertension; 2013 Oct; 62(4):775-81. PubMed ID: 23897069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE inhibition and renal protection.
    Ritz E
    Clin Physiol Biochem; 1992; 9(3):94-7. PubMed ID: 1302163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Angiotensin-converting enzyme inhibitors: effects on renal physiology and applications in hypertension and renal disease].
    Cofán F; Romero R
    Rev Clin Esp; 1993 Jan; 192(1):31-8. PubMed ID: 8465029
    [No Abstract]   [Full Text] [Related]  

  • 30. Calcium antagonists and renal failure progression.
    Robles NR
    Ren Fail; 2008; 30(3):247-55. PubMed ID: 18350443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers.
    Caldwell BV
    Clin Ther; 1993; 15(4):618-36; discussion 617. PubMed ID: 8221813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement of drug development for chronic renal disease: Other strategies than blockade of the renin-angiotensin system.
    Okamoto T
    Int J Mol Med; 2003 May; 11(5):651-4. PubMed ID: 12684706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypertension--special reference to kidney diseases].
    Hayashi M
    Nihon Jinzo Gakkai Shi; 2002; 44(5):432-8. PubMed ID: 12216475
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin converting enzyme inhibitors and calcium antagonists in the progression of renal insufficiency.
    Zucchelli P; Gaggi R; Zuccalà A
    Contrib Nephrol; 1992; 98():116-24. PubMed ID: 1493723
    [No Abstract]   [Full Text] [Related]  

  • 35. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment and renal function in patients with chronic kidney disease.
    Renke M; Rutkowski P; Tylicki L; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2010 Jun; 11(2):146-7. PubMed ID: 20223790
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of antihypertensive therapies on the sympathetic nervous system.
    de Champlain J; Karas M; Toal C; Nadeau R; Larochelle P
    Can J Cardiol; 1999 Mar; 15 Suppl A():8A-14A. PubMed ID: 10205251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.